

Michel Clanet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10899198/publications.pdf>

Version: 2024-02-01

23
papers

12,269
citations

394421
19
h-index

642732
23
g-index

23
all docs

23
docs citations

23
times ranked

13447
citing authors

#	ARTICLE	IF	CITATIONS
1	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. Journal of Neuroradiology, 2021, 48, 170-175.	1.1	4
2	Biallelic MYORG mutation carriers exhibit primary brain calcification with a distinct phenotype. Brain, 2019, 142, 1573-1586.	7.6	49
3	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	3.0	458
4	Assessment of a program to encourage the multidisciplinary management of urinary disorders in multiple sclerosis. Neurourology and Urodynamics, 2017, 36, 706-709.	1.5	1
5	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Multiple Sclerosis Journal, 2016, 22, 1719-1731.	3.0	249
6	Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients. Neurourology and Urodynamics, 2015, 34, 32-36.	1.5	37
7	A central nervous system B-cell lymphoma arising two years after initial diagnosis of CLIPPERS. Journal of the Neurological Sciences, 2014, 344, 224-226.	0.6	58
8	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
9	Mutation of the <i>PDGFRB</i> gene as a cause of idiopathic basal ganglia calcification. Neurology, 2013, 80, 181-187.	1.1	239
10	Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain, 2013, 136, 3395-3407.	7.6	183
11	Long-term Outcomes of CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular) Tj ETQq1 1 0.784314 rgBT /Overlook 2012, 69, 847-55.	4.5	109
12	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	5.3	8,001
13	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain, 2011, 134, 693-703.	7.6	96
14	A Role for <i>VAV1</i> in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Science Translational Medicine, 2009, 1, 10ra21.	12.4	52
15	Relevance of the skewness index in DTI exploration of multiple sclerosis. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2009, 22, 89-100.	2.0	1
16	Diffusion tensor imaging in multiple sclerosis: a tool for monitoring changes in normal-appearing white matter. Multiple Sclerosis Journal, 2004, 10, 188-196.	3.0	71
17	Investigation of seven proposed regions of linkage in multiple sclerosis: an American and French collaborative study. Neurogenetics, 2004, 5, 45-48.	1.4	23
18	Genetic interaction of <i>CTLA4</i> with <i>HLA-DR15</i> in multiple sclerosis patients. Annals of Neurology, 2003, 54, 119-122.	5.3	46

#	ARTICLE	IF	CITATIONS
19	Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach. Journal of Neuroimmunology, 2000, 102, 107-112.	2.3	45
20	Evidence for Linkage Disequilibrium Between HLA-DRB1 Gene and Multiple Sclerosis. Science, 1997, 276, 661g-665.	12.6	36
21	Antivertigo Medications and Drug-Induced Vertigo. Drugs, 1995, 50, 777-791.	10.9	96
22	Tumor necrosis factor polymorphisms in multiple sclerosis: No additional association independent of HLA. Journal of Neuroimmunology, 1994, 51, 93-99.	2.3	61
23	HLA-DPB1 gene polymorphism and multiple sclerosis: a large case-control study in the southwest of France. Journal of Neuroimmunology, 1991, 34, 215-222.	2.3	10